Toby Maher MD
Interstitial Lung Diseases
Professor of Clinical Medicine and Director of Interstitial Lung Disease
Join to View Full Profile
1520 San Pablo StSte 1000Los Angeles, CA 90033
Phone+1 323-442-5100
Dr. Maher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a pulmonologist specializing in the diagnosis and treatment of interstitial lung diseases including; idiopathic pulmonary fibrosis, sarcoidosis, lung disease related to connective tissue diseases and rheumatoid arthritis, chronic hypersensitivity pneumonitis, histiocytosis and LAM.
Education & Training
University of Southampton Faculty of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2020 - 2026
Clinical Trials
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17
Roles: Contact
- LYT-100 in Post-acute COVID-19 Respiratory Disease Start of enrollment: 2020 Dec 11
- Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Start of enrollment: 2022 Sep 08
- Join now to see all
Publications & Presentations
PubMed
- Publisher Correction: Fibrosis: cross-organ biology and pathways to development of innovative drugs.Florian Rieder, Laura E Nagy, Toby M Maher, Jörg H W Distler, Rafael Kramann
Nature Reviews. Drug Discovery. 2025-03-31 - Fibrosis: cross-organ biology and pathways to development of innovative drugs.Florian Rieder, Laura E Nagy, Toby M Maher, Jörg H W Distler, Rafael Kramann
Nature Reviews. Drug Discovery. 2025-03-18 - The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-co...Megan Jones, Anthony Cahn, Nazia Chaudhuri, Allan B Clark, Ian Forrest
BMJ Open. 2025-02-05
Press Mentions
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b TrialDecember 16th, 2024- Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AINovember 12th, 2024
- AI-Driven Drug Discovery Achieves Milestone with Insilico Medicine’s Phase IIa Success in Treating Pulmonary FibrosisSeptember 26th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
